Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | CTSD | P07339 | 1/20 | 0.63 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11761482 | 0.85 | NAMPT (0.71) | HPGDTP53GLACTSDHCRTR1 | |
| SCHEMBL3038950 | 0.85 | KMT2A (0.74) | STAT3HPGDTP53GLACTSD | |
| SCHEMBL6360123 | 0.85 | HPGD (0.65) | STAT3HPGDTP53GLACTSD | |
| SCHEMBL3365176 | 0.84 | CTSD (0.68) | STAT3HPGDTP53GLACTSD | |
| SCHEMBL7956519 | 0.84 | HPGD (0.63) | STAT3HPGDTP53GLACTSD | |
| SCHEMBL30848493 | 0.84 | HPGD (0.63) | STAT3HPGDTP53GLACTSD | |
| SCHEMBL9951667 | 0.83 | NPSR1 (0.67) | HPGDTP53GLACTSDKMT2A | |
| Hydrochloric Acid SCHEMBL9585041 | 0.83 | CTSD (0.66) | STAT3HPGDTP53GLACTSD | |
| SCHEMBL3199672 | 0.83 | NPSR1 (0.67) | HPGDTP53GLACTSDKMT2A | |
| SCHEMBL6360354 | 0.83 | TSHR (0.73) | HPGDTP53GLACTSDHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | STAT3 732/4885HPGD 556/4885TP53 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.